TNF-α inhibitors and IL-1 receptor antagonists are well-established therapeutic approaches for RA treatment [13–15], and antibodies against TNF-α, IL-1β, and IL-6 show positive effects during investigation of RA therapies [16, 17]. Here, IL1B is linked to rheumatoid arthritis.